Nakagawa H, et al. - Since previous studies demonstrated the potential effectiveness of delgocitinib ointment, a novel topical Janus kinase inhibitor, in atopic dermatitis (AD), researchers in the present phase 3 study, tested the safety and effectiveness of delgocitinib 0.5% ointment in Japanese adult patients (aged 16 years or older) with moderate to severe AD over a 4-week double-blind period (part 1) and a 24-week extension period (part 2). In Japanese adult patients with moderate to severe AD for up to 28 weeks, delgocitinib 0.5% ointment was effective and well-tolerated. The results of the study suggest that delgocitinib ointment represents a promising therapeutic alternative for AD. The majority of adverse events over the period of study were mild and unrelated to delgocitinib.